NLTX Annual SG&A
$17.97 M
-$3.57 M-16.57%
31 December 2022
Summary:
As of January 20, 2025, NLTX annual selling, general & administrative expenses is $17.97 million, with the most recent change of -$3.57 million (-16.57%) on December 31, 2022. During the last 3 years, it has fallen by -$858.00 thousand (-4.56%).NLTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly SG&A
$4.95 M
+$1.46 M+41.81%
30 September 2023
Summary:
As of January 20, 2025, NLTX quarterly selling, general & administrative expenses is $4.95 million, with the most recent change of +$1.46 million (+41.81%) on September 30, 2023. Over the past year, it has increased by +$814.00 thousand (+19.67%).NLTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM SG&A
-$1.86 B
-$34.26 M-1.88%
30 September 2023
Summary:
As of January 20, 2025, NLTX TTM selling, general & administrative expenses is -$1.86 billion, with the most recent change of -$34.26 million (-1.88%) on September 30, 2023. Over the past year, it has dropped by -$1.87 billion (-9799.06%).NLTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.6% | +19.7% | -9799.1% |
| 3 y3 years | -4.6% | +28.3% | -10000.0% |
| 5 y5 years | +21.0% | +10.4% | -9956.2% |
NLTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -16.6% | -52.3% | -8403.3% |
Neoleukin Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $4.95 M(+41.8%) | $16.72 M(+5.1%) |
| June 2023 | - | $3.49 M(-13.3%) | $15.91 M(-8.2%) |
| Mar 2023 | - | $4.03 M(-5.2%) | $17.33 M(-3.5%) |
| Dec 2022 | $17.97 M(-16.6%) | $4.25 M(+2.7%) | $17.97 M(-6.1%) |
| Sept 2022 | - | $4.14 M(-15.8%) | $19.13 M(-6.9%) |
| June 2022 | - | $4.92 M(+5.4%) | $20.55 M(-1.8%) |
| Mar 2022 | - | $4.66 M(-13.9%) | $20.93 M(-2.7%) |
| Dec 2021 | $21.54 M(+25.1%) | $5.41 M(-2.6%) | $21.51 M(+2.7%) |
| Sept 2021 | - | $5.56 M(+4.8%) | $20.95 M(+8.8%) |
| June 2021 | - | $5.30 M(+1.1%) | $19.25 M(+2.0%) |
| Mar 2021 | - | $5.24 M(+8.0%) | $18.88 M(+9.7%) |
| Dec 2020 | $17.21 M(-8.6%) | $4.85 M(+25.7%) | $17.21 M(+8.7%) |
| Sept 2020 | - | $3.86 M(-21.6%) | $15.83 M(-29.2%) |
| June 2020 | - | $4.93 M(+37.9%) | $22.35 M(+12.6%) |
| Mar 2020 | - | $3.57 M(+3.0%) | $19.84 M(+5.4%) |
| Dec 2019 | $18.83 M(+18.9%) | $3.47 M(-66.6%) | $18.83 M(+4.1%) |
| Sept 2019 | - | $10.38 M(+328.4%) | $18.09 M(+48.4%) |
| June 2019 | - | $2.42 M(-5.2%) | $12.19 M(-13.4%) |
| Mar 2019 | - | $2.56 M(-6.3%) | $14.08 M(-11.1%) |
| Dec 2018 | $15.84 M | $2.73 M(-39.2%) | $15.84 M(-12.4%) |
| Sept 2018 | - | $4.48 M(+3.9%) | $18.08 M(+5.1%) |
| June 2018 | - | $4.31 M(+0.1%) | $17.21 M(+4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $4.31 M(-13.4%) | $16.42 M(+10.5%) |
| Dec 2017 | $14.85 M(+60.3%) | $4.97 M(+37.6%) | $14.85 M(+12.4%) |
| Sept 2017 | - | $3.61 M(+2.7%) | $13.21 M(+12.5%) |
| June 2017 | - | $3.52 M(+28.2%) | $11.74 M(+16.8%) |
| Mar 2017 | - | $2.75 M(-17.6%) | $10.05 M(+8.6%) |
| Dec 2016 | $9.26 M(+67.2%) | $3.33 M(+55.0%) | $9.26 M(+21.9%) |
| Sept 2016 | - | $2.15 M(+17.4%) | $7.60 M(+13.8%) |
| June 2016 | - | $1.83 M(-6.3%) | $6.68 M(+10.9%) |
| Mar 2016 | - | $1.95 M(+17.2%) | $6.02 M(+8.7%) |
| Dec 2015 | $5.54 M(+29.0%) | $1.67 M(+35.5%) | $5.54 M(+3.2%) |
| Sept 2015 | - | $1.23 M(+4.9%) | $5.37 M(+4.7%) |
| June 2015 | - | $1.17 M(-20.3%) | $5.13 M(+1.8%) |
| Mar 2015 | - | $1.47 M(-1.4%) | $5.03 M(+17.2%) |
| Dec 2014 | $4.30 M(+141.8%) | $1.49 M(+51.3%) | $4.30 M(+22.9%) |
| Sept 2014 | - | $987.00 K(-8.7%) | $3.49 M(+20.6%) |
| June 2014 | - | $1.08 M(+47.1%) | $2.90 M(+32.5%) |
| Mar 2014 | - | $735.00 K(+6.3%) | $2.19 M(+16.6%) |
| Dec 2013 | $1.78 M(+8.6%) | $691.40 K(+77.3%) | $1.88 M(+58.4%) |
| Sept 2013 | - | $389.90 K(+5.4%) | $1.18 M(+49.1%) |
| June 2013 | - | $369.80 K(-12.8%) | $793.70 K(+87.2%) |
| Mar 2013 | - | $423.90 K | $423.90 K |
| Dec 2012 | $1.64 M | - | - |
FAQ
- What is Neoleukin Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual SG&A year-on-year change?
- What is Neoleukin Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly SG&A year-on-year change?
- What is Neoleukin Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM SG&A year-on-year change?
What is Neoleukin Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of NLTX is $17.97 M
What is the all time high annual SG&A for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual selling, general & administrative expenses is $21.54 M
What is Neoleukin Therapeutics annual SG&A year-on-year change?
Over the past year, NLTX annual selling, general & administrative expenses has changed by -$3.57 M (-16.57%)
What is Neoleukin Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of NLTX is $4.95 M
What is the all time high quarterly SG&A for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly selling, general & administrative expenses is $10.38 M
What is Neoleukin Therapeutics quarterly SG&A year-on-year change?
Over the past year, NLTX quarterly selling, general & administrative expenses has changed by +$814.00 K (+19.67%)
What is Neoleukin Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of NLTX is -$1.86 B
What is the all time high TTM SG&A for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM selling, general & administrative expenses is $22.35 M
What is Neoleukin Therapeutics TTM SG&A year-on-year change?
Over the past year, NLTX TTM selling, general & administrative expenses has changed by -$1.87 B (-9799.06%)